A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome

Brief description of study

The purpose of this study is to test two different dose levels of ARO-APOC3 administered 4 times, 3 months apart in people with Familial Chylomicronemia Syndrome (FCS). The intention is to test the efficacy and safety of ARO-APOC3, as well as the pharmacokinetics (PK - how your body uses the study drug) and pharmacodynamics (PD - how the study drug affects your body) of the study drug. ARO-APOC3 is an experimental drug. This means that it is not approved by the United States Food and Drug Administration (FDA) for marketing. While ARO-APOC3 has already been tested in healthy participants and participants with hypertriglyceridemia, the potential therapeutic benefits and side effects in people with FCS are still being studied.

Clinical Study Identifier: s21-01153
ClinicalTrials.gov Identifier: NCT05089084
Principal Investigator: Ira J Goldberg.
Other Investigator: Akankasha Goyal.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.